Table 2.

Clinical studies on-going infusing CAR-NK cells in cancer patients.

NCT Number Institution	Type of NK/CAR-Co-Stimulatory Domains	Disease	Treatment/Doses
NCT02892695 PersonGen BioTherapeutics	NK-92 Anti-CD19-CD28, 4-1BB	Relapsed/refractory ALL, CLL, FL, BCL, DLBCL	NK before SCT
NCT02944162 PersonGen BioTherapeutics	NK-92 Anti-CD33-CD28, CD137	Relapsed/refractory CD33+ AML	NK on Days 0, 3 and 5
NCT02742727 PersonGen BioTherapeutics	NK92 Anti-CD7- CD28, 4-1BB	Relapsed/refractory CD7 positive leukemias and lymphomas	NK
NCT03056339 M.D.Anderson Cancer Center	CB-NK expanded with K562-mb21 Anti-CD19, 4-1BB, CD28, iCasp9, IL15	B-cell malignancies: ALL, CLL, NHL	Day-5 to -3: Flu, Cy, Mesna Day 0: NK AP1903 in case of CRS or GVHD
NCT02839954 PersonGen BioTherapeutics	NA	Relapsed/refractory Muc1 positive solid tumors	NA
NCT01974479 National University Health system, Singapore	Haploidentical NK expanded with K562-mb15-41BBL Anti-CD19, 4-1BB	Refractory ALL	NK
NCT00995137 St. Jude Children‘s Research Hospital	Haploidentical NK expanded with K562-mb15-41BBL Anti-CD19, 4-1BB	Refractory ALL	NK

ALL: acute lympoblastic leukemia; CLL: chronic lymphocytic leukemia; FL: follicular lymphoma; BCL: B cell lymphoma; MCL: mantle cell lymphoma; DLBCL: diffuse large cell lymphoma; AML: acute myeloid leukemia; NHL: non Hodgkin Lymphoma; Flu: fludarabine; Cy: cyclophosphamide; NA: information not specified